These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 8602023)

  • 21. Surfaceome analysis of Australian epidemic Bordetella pertussis reveals potential vaccine antigens.
    Luu LDW; Octavia S; Aitken C; Zhong L; Raftery MJ; Sintchenko V; Lan R
    Vaccine; 2020 Jan; 38(3):539-548. PubMed ID: 31703933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants.
    Tapiainen T; Cherry JD; Heininger U
    Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serologic response and antibody-titer decay in adults with pertussis.
    Heininger U; Cherry JD; Stehr K
    Clin Infect Dis; 2004 Feb; 38(4):591-4. PubMed ID: 14765356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum reactome induced by Bordetella pertussis infection and Pertussis vaccines: qualitative differences in serum antibody recognition patterns revealed by peptide microarray analysis.
    Valentini D; Ferrara G; Advani R; Hallander HO; Maeurer MJ
    BMC Immunol; 2015 Jul; 16():40. PubMed ID: 26129684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serological correlates in whooping cough.
    Granström M; Granström G
    Vaccine; 1993; 11(4):445-8. PubMed ID: 8470429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Local and systemic immune responses to pertussis infection and cellular and acellular vaccines.
    Ashworth LA; Day A; Lambert HP; Lingham S; Lissauer T; Miller E; Robinson A; Rutter DA; Thomas MG
    Ann Sclavo Collana Monogr; 1986; 3(1-2):199-211. PubMed ID: 2892507
    [No Abstract]   [Full Text] [Related]  

  • 27. Serum IgG antibody response to pertussis toxin in persons for whom pertussis vaccination failed depends upon the number of antigens in the vaccine.
    Cherry JD
    Clin Infect Dis; 1999 Mar; 28(3):560-1. PubMed ID: 10194078
    [No Abstract]   [Full Text] [Related]  

  • 28. Antibody responses after vaccination and disease against leukocytosis promoting factor, filamentous hemagglutinin, lipopolysaccharide and a protein binding to complement-fixing antibodies induced during whooping cough.
    Winsnes R; Lønnes T; Møgster B; Berdal BP
    Dev Biol Stand; 1985; 61():353-65. PubMed ID: 2872124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
    Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines.
    Steinhoff MC; Reed GF; Decker MD; Edwards KM; Englund JA; Pichichero ME; Rennels MB; Anderson EL; Deloria MA; Meade BD
    Pediatrics; 1995 Sep; 96(3 Pt 2):567-70. PubMed ID: 7659477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whole-cell and acellular pertussis vaccines.
    Wintermeyer SM; Nahata MC; Kyllonen KS
    Ann Pharmacother; 1994; 28(7-8):925-39. PubMed ID: 7949515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of Bordetella pertussis filamentous hemagglutinin with human TLR2: identification of the TLR2-binding domain.
    Asgarian-Omran H; Amirzargar AA; Zeerleder S; Mahdavi M; van Mierlo G; Solati S; Jeddi-Tehrani M; Rabbani H; Aarden L; Shokri F
    APMIS; 2015 Feb; 123(2):156-62. PubMed ID: 25353353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pertussis vaccines: present status.
    Christodoulides M
    Adv Biotechnol Processes; 1990; 13():169-99. PubMed ID: 2185783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of 13 acellular pertussis vaccines: overview and serologic response.
    Edwards KM; Meade BD; Decker MD; Reed GF; Rennels MB; Steinhoff MC; Anderson EL; Englund JA; Pichichero ME; Deloria MA
    Pediatrics; 1995 Sep; 96(3 Pt 2):548-57. PubMed ID: 7659475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen.
    Hijnen M; Mooi FR; van Gageldonk PG; Hoogerhout P; King AJ; Berbers GA
    Infect Immun; 2004 Jul; 72(7):3716-23. PubMed ID: 15213111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution of Bordetella pertussis.
    He Q
    Pediatr Infect Dis J; 2016 Aug; 35(8):915-7. PubMed ID: 27213264
    [No Abstract]   [Full Text] [Related]  

  • 37. Dynamics of transplacental transmission of pertussis antibodies in premature and full-term infants.
    Nomura M; Kuno-Sakai H; Kimura M; Ichikawa I
    Tokai J Exp Clin Med; 2003 Apr; 28(1):21-6. PubMed ID: 12880300
    [No Abstract]   [Full Text] [Related]  

  • 38. [Acellular pertussis vaccine].
    Wiedermann G; Ambrosch F; Vanura H
    Wien Med Wochenschr; 1991; 141(12):270-2. PubMed ID: 1949820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How to make sense of pertussis immunogenicity data.
    Olin P; Hallander HO; Gustafsson L; Reizenstein E; Storsaeter J
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S288-91. PubMed ID: 11709761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization.
    Hausman SZ; Burns DL
    Infect Immun; 2000 Jun; 68(6):3763-7. PubMed ID: 10816544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.